Literature DB >> 10973250

In vivo selection using a cell-growth switch.

L Jin1, H Zeng, S Chien, K G Otto, R E Richard, D W Emery, C A Blau.   

Abstract

A major obstacle to stem-cell gene therapy rests in the inability to deliver a gene into a therapeutically relevant fraction of stem cells. One way to circumvent this obstacle is to use selection. Vectors containing two linked genes serve as the basis for selection, with one gene encoding a selectable product and the other, a therapeutic protein. Applying selection in vivo has the potential to bring a minor population of genetically corrected cells into the therapeutic range. But strategies for achieving in vivo selection have traditionally relied on genes that confer resistance to cytotoxic drugs and are encumbered by toxicity. Here we describe a new system for in vivo selection that uses a 'cell-growth switch', allowing a minor population of genetically corrected cells into the therapeutic range. But strategies for achieving in vivo selection have traditionally relied on genes that confer resistance to cytotoxic drugs and are encumbered by toxicity. Here we describe a new system for in vivo selection that uses a 'cell-growth switch', allowing a minor population of genetically modified cells to be inducibly amplified, thereby averting the risks associated with cytotoxic drugs. This system provides a general platform for conditionally expanding genetically modified cell populations in vivo, and may have widespread applications in gene and cell therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10973250     DOI: 10.1038/79194

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  22 in total

1.  Gene correction in hematopoietic progenitor cells by homologous recombination.

Authors:  S Hatada; K Nikkuni; S A Bentley; S Kirby; O Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells.

Authors:  Shengming Zhao; Karen Zoller; Masayoshi Masuko; Ponlapat Rojnuckarin; Xuexian O Yang; Evan Parganas; Kenneth Kaushansky; James N Ihle; Thalia Papayannopoulou; Dennis M Willerford; Tim Clackson; C Anthony Blau
Journal:  EMBO J       Date:  2002-05-01       Impact factor: 11.598

Review 3.  Hematopoietic stem cell gene therapy.

Authors:  David W Emery; Tamon Nishino; Ken Murata; Michalis Fragkos; George Stamatoyannopoulos
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

Review 4.  Selective expansion of transduced cells for hematopoietic stem cell gene therapy.

Authors:  Akihiro Kume; Yutaka Hanazono; Hiroaki Mizukami; Takashi Okada; Keiya Ozawa
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

5.  Self-Destruct Genetic Switch to Safeguard iPS Cells.

Authors:  Zoltán Ivics
Journal:  Mol Ther       Date:  2015-09       Impact factor: 11.454

6.  Growth factor receptors as regulators of hematopoiesis.

Authors:  Michael A Weinreich; Ingrid Lintmaer; Linlin Wang; H Denny Liggitt; Michael A Harkey; C Anthony Blau
Journal:  Blood       Date:  2006-08-10       Impact factor: 22.113

7.  FGFR4 and its novel splice form in myogenic cells: Interplay of glycosylation and tyrosine phosphorylation.

Authors:  Boguslaw A Kwiatkowski; Irina Kirillova; Robert E Richard; David Israeli; Zipora Yablonka-Reuveni
Journal:  J Cell Physiol       Date:  2008-06       Impact factor: 6.384

8.  Long-term regulation of genetically modified primary hematopoietic cells in dogs.

Authors:  Kiyoshi Okazuka; Brian C Beard; David W Emery; Kerstin Schwarzwaelder; Michele R Spector; George E Sale; Christof von Kalle; Beverly Torok-Storb; Hans-Peter Kiem; C Anthony Blau
Journal:  Mol Ther       Date:  2011-02-15       Impact factor: 11.454

9.  Safeguarding nonhuman primate iPS cells with suicide genes.

Authors:  Bonan Zhong; Korashon L Watts; Jennifer L Gori; Martin E Wohlfahrt; Joerg Enssle; Jennifer E Adair; Hans-Peter Kiem
Journal:  Mol Ther       Date:  2011-05-17       Impact factor: 11.454

10.  A hyperactive Mpl-based cell growth switch drives macrophage-associated erythropoiesis through an erythroid-megakaryocytic precursor.

Authors:  Eyayu Belay; Chris P Miller; Amanda N Kortum; Beverly Torok-Storb; C Anthony Blau; David W Emery
Journal:  Blood       Date:  2014-10-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.